Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...

Smart devices that utilise artificial intelligence have enormous potential to treat heart disease and, with the right ...

Data from ATH434-201 double-blind Phase 2 trial to be featured in oral session and multiple poster presentations –MELBOURNE, Australia and SAN ...

Seventeen-year-old East Bay football player was paralyzed and died after a swimming accident in April. His parents filed a ...

A copy of the Company’s presentation will be available under the Presentations tab of the Tonix website at https://ir.tonixpharma.com/presentations following the conference. Additional meeting ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.